This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down MT
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash CI
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief MT
NeuroBo Pharmaceuticals, Inc. Announces the Appointment of Marshall Woodworth as Chief Financial Officer CI
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity CI
US Equity Markets Close Higher Thursday Following Jobless Claims Data MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading MT
Top Midday Gainers MT
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar MT
NeuroBo Shares Surge as Obesity Drug Moves to Phase I Trial DJ
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment CI
Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash CI
NeuroBo Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Rule MT
NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise MT
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity CI
Top Premarket Gainers MT
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee CI
NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Principal Financial Officer and Principal Accounting Officer CI
NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer CI
NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon Kim from the Board of Directors CI
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash CI
Chart NeuroBo Pharmaceuticals, Inc.
More charts
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused primarily on therapies for cardiometabolic diseases. Its therapeutics programs include DA-1241 and DA-1726. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist. OXM is a naturally occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists. Each of DA-1241 and DA-1726 is being developed for the treatment of nonalcoholic steatohepatitis.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.53 USD
Average target price
36.5 USD
Spread / Average Target
+933.99%
Consensus
  1. Stock Market
  2. Equities
  3. NRBO Stock
  4. News NeuroBo Pharmaceuticals, Inc.
  5. NeuroBo Pharmaceuticals Implements 1-For-30 Reverse Stock Split